Basic fibroblast growth factor increases the transplantation-mediated therapeutic effect of bone mesenchymal stem cells following traumatic brain injury

Liu, Yang; Yi, Xiuli; Guo, Geng; Long, Qianfa; Wang, Xiao‐An; Zhong, Jun; Liu, Wei‑Ping; Zhou, Fei; Wang, Dong‐Mei; Li, Jun

doi:10.3892/mmr.2013.1803

Cited by 21 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 24 Nevertheless, by delivering FGF-2 with bone marrow derived MSCs by stereotactic injection, Bhang and colleagues 28 found increased expression of neuronal and astrocytic markers and improvement in animal motor function. Liu and colleagues 36 directly injected FGF-2 into the lateral ventricle and showed a higher survival rate in transplanted bone marrow derived MSCs and increased differentiation into neuronal and glial cells, but no functional recovery.…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Cell-Based therapy for traumatic brain injury

Gennai

Monsel

Qin

et al. 2015

British Journal of Anaesthesia

View full text Add to dashboard Cite

Traumatic brain injury is a major economic burden to hospitals in terms of emergency department visits, hospitalizations, and utilization of intensive care units. Current guidelines for the management of severe traumatic brain injuries are primarily supportive, with an emphasis on surveillance (i.e. intracranial pressure) and preventive measures to reduce morbidity and mortality. There are no direct effective therapies available. Over the last fifteen years, pre-clinical studies in regenerative medicine utilizing cell-based therapy have generated enthusiasm as a possible treatment option for traumatic brain injury. In these studies, stem cells and progenitor cells were shown to migrate into the injured brain and proliferate, exerting protective effects through possible cell replacement, gene and protein transfer, and release of anti-inflammatory and growth factors. In this work, we reviewed the pathophysiological mechanisms of traumatic brain injury, the biological rationale for using stem cells and progenitor cells, and the results of clinical trials using cell-based therapy for traumatic brain injury. Although the benefits of cell-based therapy have been clearly demonstrated in pre-clinical studies, some questions remain regarding the biological mechanisms of repair and safety, dose, route and timing of cell delivery, which ultimately will determine its optimal clinical use.

show abstract

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Cell-Based therapy for traumatic brain injury

Gennai

Monsel

Qin

et al. 2015

British Journal of Anaesthesia

View full text Add to dashboard Cite

show abstract

“…As a result, it is imperative to deliver the growth factors into the brain near the injury. Liu et al showed that intracerebroventricular administration of fibroblast growth factor 2 (FGF2) for 7 days beginning at the time of MSC transplantation resulted in faster improvement in the forelimb placing and balance beam tests compared to the no treatment TBI group and the cell‐only group. Insulin‐like growth factor‐1 known to have a crucial role in MSC proliferation and putative differentiation to neuronal cells .…”

Section: Cell Therapy In Tbimentioning

confidence: 99%

Potential of mesenchymal stem cells alone, or in combination, to treat traumatic brain injury

et al. 2020

View full text Add to dashboard Cite

Traumatic brain injury (TBI) causes death and disability in the United States and around the world. The traumatic insult causes the mechanical injury of the brain and primary cellular death. While a comprehensive pathological mechanism of TBI is still lacking, the focus of the TBI research is concentrated on understanding the pathophysiology and developing suitable therapeutic approaches. Given the complexities in pathophysiology involving interconnected immunologic, inflammatory, and neurological cascades occurring after TBI, the therapies directed to a single mechanism fail in the clinical trials. This has led to the development of the paradigm of a combination therapeutic approach against TBI. While there are no drugs available for the treatment of TBI, stem cell therapy has shown promising results in preclinical studies. But, the success of the therapy depends on the survival of the stem cells, which are limited by several factors including route of administration, health of the administered cells, and inflammatory microenvironment of the injured brain. Reducing the inflammation prior to cell administration may provide a better outcome of cell therapy following TBI. This review is focused on different therapeutic approaches of TBI and the present status of the clinical trials.

show abstract

“…In recent years, several studies have investigated the potential neuroprotective effects of stem cells and their ability to stimulate endogenous regeneration in animal models of TBI (7)(8)(9)(10)(11). Although the functional mechanisms of this therapy have yet to be determined, these previous studies demonstrated that stem cell administration improves functional recovery following TBI in experimental animals.…”

Section: Introductionmentioning

confidence: 99%

Safety of neural stem cell transplantation in patients with severe traumatic brain injury

et al. 2017

View full text Add to dashboard Cite

Abstract. Neural stem cell (NSC) therapy is a promising treatment for traumatic brain injury (TBI). In addition, mesenchymal stem cells (MSCs) have been investigated for the treatment of TBI due to their functions in neural regeneration and their neurotrophic effect. In the present study, the safety, feasibility and biological effects of autologous MSC-derived NSC-like cell transplantation were investigated in 10 patients with severe TBI. All patients received intravenous or intrathecal injections of human NSC-like cells and were evaluated with physical and neurological examinations, routine laboratory tests and neuroradiological findings. The results indicated that the majority of patients experienced improved neurological function in different degrees during the follow-up period. No mortality or serious adverse events were observed in any patient subsequent to transplantation. Higher serum levels of nerve growth factor and brain-derived neurotrophic factor were detected following the transplantation, as compared with the levels prior to treatment. Overall, the present results suggest that transplantation of autologous NSC-like cells is feasible and appears to be safe for the treatment of non-acute severe TBI.

show abstract

Basic fibroblast growth factor increases the transplantation-mediated therapeutic effect of bone mesenchymal stem cells following traumatic brain injury

Cited by 21 publications

References 27 publications

Cell-Based therapy for traumatic brain injury

Cell-Based therapy for traumatic brain injury

Potential of mesenchymal stem cells alone, or in combination, to treat traumatic brain injury

Safety of neural stem cell transplantation in patients with severe traumatic brain injury

Contact Info

Product

Resources

About